A structural reset for a global operator

Ramsay Health Care, the operator of scores of private hospitals across Australia and, through its European associate, continental markets, is midway through the most significant reshaping of its corporate structure in years. At the centre sits a plan, announced on 20 February 2026, to distribute the company’s 52.79 per cent shareholding in Paris-listed Ramsay Sante to Ramsay shareholders by way of an in-specie distribution, implemented through a scheme of arrangement under Australian law.

If completed, the transaction would sever the direct equity link between the Australian parent and its long-held French arm, leaving Ramsay as a substantially Australian and United Kingdom-focused hospital group. Management has framed the move as a way to “simplify Ramsay and enable both organisations to focus on transforming their respective businesses,” with chief executive Natalie Davis positioning the domestic operation as the primary engine of future value.

 

The half-year that reframed the story

The separation plan landed alongside interim results, reported on 26 February 2026 for the six months ended 31 December 2025, that showed a marked improvement on a heavily impaired prior corresponding period.

On a statutory basis, net profit after tax was A$160.7 million, against a loss of A$104.9 million a year earlier, when the result carried non-cash writedowns. Statutory earnings before interest and tax rose sharply to A$520.4 million. Revenue increased 9.3 per cent to A$9,378.4 million.

Investors should distinguish those headline figures from the company’s preferred underlying measures, which strip out items management regards as non-recurring. On that basis, underlying net profit after tax rose 8.1 per cent to A$171.7 million and underlying EBIT increased 7.3 per cent to A$536.7 million. The directors declared a fully franked interim dividend of 42.5 cents per share, up 6.3 per cent from 40.0 cents, representing a payout of about 60 per cent of underlying earnings and paid on 26 March 2026.

Shares in Ramsay advanced in the sessions following the release as investors assessed the combination of a profit rebound, a higher dividend and the demerger plan. The magnitude of any single-day move should be treated cautiously in the absence of an independently verified figure.

 

Australia does the heavy lifting

The domestic division remains the group’s largest and, increasingly, its clearest growth story. Australian underlying EBIT rose 7.1 per cent to A$330.9 million, supported by admissions growth of 3.1 per cent and a shift toward higher-acuity procedures. Management pointed to margin gains excluding the Joondalup facility, where a large expansion is still ramping, and said mitigation initiatives at that site — including agency-cost reduction — remained on track.

Ms Davis has tied the Australian turnaround to a narrower set of operational priorities: revenue-cycle and patient-administration system upgrades, workforce optimisation through smarter rostering, and technology to track prostheses and consumables. The company reported theatre-utilisation gains even as it opened new theatres, which it presented as evidence of more disciplined capacity management rather than simple volume expansion.

Growth ambitions are not solely organic. Ramsay expects to complete the acquisition of National Capital Private Hospital in Canberra early in FY27, describing the asset as offering an attractive catchment and clinical reputation, and flagging first-year earnings-per-share accretion. Detailed financial terms were not disclosed.

 

The French question, and why it is being spun off

Ramsay Sante has long complicated the group’s narrative. French private hospital operators face constrained public tariff indexation and periodic political pressure on funding, dynamics that have weighed on reported margins. In its results for the nine months to 31 March 2026, Ramsay Sante posted revenue of EUR3,981.3 million, up 3.1 per cent, with EBITDA of EUR460.4 million at an 11.6 per cent margin and operating profit up 16.0 per cent to EUR134.0 million. The associate remained loss-making at the net level on a group-share basis, though the loss narrowed to EUR27.9 million, and it absorbed a roughly EUR20 million reduction in the French revenue guarantee.

Nordic operations provided ballast, with the renewed St Goran hospital contract in Stockholm — valued at about EUR4.8 billion over 12 years — commencing in January 2026 on improved pricing terms.

Notably, within the Australian group’s own accounts, the Ramsay Sante contribution rose. Underlying EBIT attributable to the European arm increased 14.2 per cent to A$116.7 million for the half. Separating a unit that is currently growing its earnings contribution underscores that the rationale is strategic clarity and capital-structure simplification rather than a distressed exit. Ramsay has said the in-specie structure is more tax-efficient for shareholders than a cash sale and preserves their optionality to hold or sell.

 

Timetable and financing groundwork

The company has sketched an indicative path: a demerger booklet to shareholders around October 2026, a shareholder vote on the scheme in November 2026, and targeted implementation in the December quarter, subject to board, shareholder, court and regulatory approvals. The shareholders’ agreement with Credit Agricole Assurances is set to terminate on 1 October 2026.

Supporting the split, Ramsay Sante confirmed on 22 July 2026 that it had progressed a EUR1.75 billion senior debt refinancing — comprising a EUR1.55 billion term loan and a EUR200 million revolving facility — extending maturities toward 2033 and incorporating change-of-control provisions structured to accommodate the contemplated distribution. That refinancing gives the French business a standalone financing framework ahead of any independence.

 

Balance sheet and outlook

Group leverage stood at 2.2 times, within Ramsay’s stated target of below 2.5 times. For FY26, the company guided to capital expenditure of A$755-795 million, an underlying tax rate near 35 per cent and net financing expense of A$590-610 million, while cautioning that UK activity faced pressure from NHS budget constraints, with the Elysium mental-health turnaround still under way.

For shareholders, the coming months will test whether a simplified, Australia-led Ramsay can convert operational momentum into durable returns once the European chapter is formally spun out.

This article is general information only and does not constitute financial advice; readers should consider their circumstances and seek licensed advice before making investment decisions.